Hyzetimibe vs Obicetrapib/ezetimibe (Evlarco)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atherosclerotic Cardiovascular Disease
Shared mechanism: NPC1L1 · full Atherosclerotic Cardiovascular Disease pipeline
Hyzetimibe
Marketed by Zhejiang Hisun Pharmaceutical
NCT03413462 · Phase 3 · completed
The trial randomized 374 participants to HS-25 or placebo and masked participants, investigators, and outcome assessors. Its primary endpoint was the surrogate measure of percent change in LDL-C, and because no primary-outcome results or statistical comparison are available, whether the endpoint was met is unknown.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Reported efficacy
Percent change of LDL-C (2,4,8,12 weeks): LDL-C percent change from baseline (primary endpoint, week 12): -16.39% (95% CI -19.04 to -13.74) with hyzetimibe (HS-25, referred to in this paper as hybutimibe) + atorvastatin vs -6.75% (95% CI -9.48 to -4.02) with atorvastatin alone, P<0.0001 (met)
Result source: NCT03433196
Obicetrapib/ezetimibe (Evlarco)
Marketed by A. Menarini under a licence from NewAmsterdam Pharma
NCT06005597 · Phase 3 · completed
The study was randomized, quadruple-blind, and placebo- and active-controlled, with 407 participants distributed across four treatment groups. All four prespecified LDL-C comparisons significantly favored the obicetrapib-containing treatment, but LDL-C is a laboratory surrogate rather than a hard clinical endpoint, so the evidence is rated moderate.
Reported efficacy
Effect of Fixed-Dose Combination (FDC) Compared to Placebo on LDL-C (84 Days); Effect of Fixed Dose Combination (FDC) Compared to Ezetimibe Monotherapy on LDL-C (84 Days); Effect of Fixed Dose Combination (FDC) Compared to Obicetrapib Monotherapy on LDL-C (84 Days); Effect of Obicetrapib Monotherapy Compared to Placebo on LDL-C (84 Days): Effect of Fixed-Dose Combination (FDC) Compared to Placebo on LDL-C (84 Days): Fixed Dose Combination -45.58% (Standard Error 3.465) vs Placebo 3.03% (Standard Error 3.564) (met)
Result source: NCT06005597
Results for Atherosclerotic Cardiovascular Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Hyzetimibe | Obicetrapib/ezetimibe (Evlarco) |
|---|---|---|
| LDL-C, % change | -16.4% vs -6.8%avs atorvastatin aloneNCT03433196 | —Not reported |
| Non-HDL-C, % change | —Not posted · NCT03433196 | —Not reported |
| ApoB, % change | —Not posted · NCT03433196 | —Not reported |
| Lp(a), % change | —Not posted · NCT03433196 | —Not reported |
| 3-point MACE (% with event) | —Not posted · NCT03433196 | —Not reported |
LDL-C, % change
- Hyzetimibe
- -16.4% vs -6.8%avs atorvastatin aloneNCT03433196
- Obicetrapib/ezetimibe (Evlarco)
- —Not reported
Non-HDL-C, % change
- Hyzetimibe
- —Not posted · NCT03433196
- Obicetrapib/ezetimibe (Evlarco)
- —Not reported
ApoB, % change
- Hyzetimibe
- —Not posted · NCT03433196
- Obicetrapib/ezetimibe (Evlarco)
- —Not reported
Lp(a), % change
- Hyzetimibe
- —Not posted · NCT03433196
- Obicetrapib/ezetimibe (Evlarco)
- —Not reported
3-point MACE (% with event)
- Hyzetimibe
- —Not posted · NCT03433196
- Obicetrapib/ezetimibe (Evlarco)
- —Not reported
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Hyzetimibe
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Hyzetimibe's landscape · Obicetrapib/ezetimibe (Evlarco)'s landscape